WASHINGTON, June 8, 2021 /PRNewswire/ — The Antimicrobials Working Group (AWG) announced today the addition of Crestone, Inc. (Crestone) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new addition brings AWG’s membership to 12 antimicrobial drug companies. Crestone is a clinical stage biopharmaceutical company focused...
Author: brian@
UTILITY therapeutics Announces Scientific Advisory Board
SAB includes key opinion leaders for infectious diseases and urinary tract infections.
Qpex Biopharma Initiates Phase 1 Study of ORAvance™ for Oral Treatment of Drug-Resistant Gram-Negative Bacterial Infections
SAN DIEGO, May 12, 2021 – Qpex Biopharma, Inc., (Qpex) a resistance-focused clinical-stage biopharmaceutical company discovering and developing innovative anti-infective therapies, announced that the first patient has been dosed in a Phase 1 study of ORAvance™, an ultra-broad-spectrum oral beta-lactamase inhibitor for use in combination with beta-lactam antibiotics for drug-resistant gram-negative bacterial infections.
Venatorx Pharmaceuticals Expands Anti-Infective Portfolio with HBV Candidate
VNRX-9945 Selected as 3rd Generation Hepatitis B Virus Orally Bioavailable CpAM; Clinical Trial Application and Phase 1 Planned for Second Quarter 2021
UTILITY Therapeutics Appoints Larry Edwards to the Board of Directors
LONDON, UK / ACCESSWIRE / March 1, 2021 / UTILITY therapeutics Ltd., a biotechnology company focused on the U.S. development and commercialization of two European-approved antibiotics for the treatment of urinary tract infections (UTI), announced today that Larry G. Edwards has been appointed to the Company’s Board of Directors.
UTILITY Therapeutics Joins Antimicrobials Working Group
WASHINGTON, February 17, 2021 /PRNewswire/ — The Antimicrobials Working Group (AWG) announced today the addition of UTILITY therapeutics Ltd. (UTILITY) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new addition brings AWG’s membership to 13 antimicrobial drug companies. UTILITY is focused on developing and commercializing...
Venatorx Pharmaceuticals Names New Head of Regulatory Affairs
Chitrananda Abeygunawardana, Ph.D. will lead the development and execution of Venatorx’s global regulatory strategy for its clinical and pre-clinical anti-infectives programs
Antimicrobials Working Group Announces Updates to Leadership Team
WASHINGTON, Jan. 27, 2021 /PRNewswire/ — The Antimicrobials Working Group (AWG) announced today the appointment of a new Chairperson, Ciara Kennedy, Ph.D., President and Chief Executive Officer of Amplyx Pharmaceuticals, Inc. Dr. Kennedy replaces Evan Loh, M.D., Chief Executive Officer of Paratek Pharmaceuticals, Inc., who has completed his two-year term as Chairman of AWG. Dr....
Qpex Biopharma Initiates Phase 1 Clinical Trial of QPX7728 for Drug-Resistant Bacterial Infections
Qpex Biopharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of innovative anti-infective therapies, announced today that it has initiated a Phase 1 clinical study of QPX7728, its novel ultra-broad-spectrum beta-lactamase inhibitor.
Venatorx Pharmaceuticals Names Robert Waltermire, Ph.D. Senior Vice President, CMC
MALVERN, Pa.--(BUSINESS WIRE)--Venatorx Pharmaceuticals today announced that Robert Waltermire, Ph.D. has joined the Company as Senior Vice President, Chemistry, Manufacturing and Controls (“CMC”).